Under-use of secondary prevention medication in acute coronary syndrome patients treated with in-hospital coronary artery bypass graft surgery

New Zealand Medical Journal

Volumn 124, Issue 1343, 2011, Pages 18-27

  Looi, Khang L ^a   Chow, Kok L ^a   Looi, Jen L ^a   Lee, Mildred ^a   Halliday, Sue ^a   White, Harvey ^a   Ellis, Chris ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SECONDARY PREVENTION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CARDIAC OUTPUT; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY BYPASS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEW ZEALAND; PROSPECTIVE STUDIES; RISK FACTORS; SECONDARY PREVENTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80053190650     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ministry of Health. Mortality and Demographic Data 2007. Wellington: Ministry of Health; 2010. http://www.moh.govt.nz/moh.nsf/indexmh/mortality-demographic-data-2007
2. Charlson ME, Isom OW. Care after Coronary-Artery Bypass Surgery. New England Journal of Medicine 2003;348:1456-63
3. Smith SC, Jr., Allen J, Blair SN, et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72
4. Eagle K, Guyton R, Davidoff R, et al. ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery. Circulation 2004;110:e340-e437
5. Ellis CJ, French JK, White HD, et al. Results of percutaneous coronary angioplasty in patients < 40 years of age. The American Journal of Cardiology 1998;82:135-139
6. French JK, Scott DS, Whitlock RML, et al. Late Outcome After Coronary Artery Bypass Graft Surgery in Patients <40 Years Old. Circulation 1995;92:9-14
7. Mangano DT. Aspirin and Mortality from Coronary Bypass Surgery. New England Journal of Medicine 2002;347:1309-1317
8. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202-1208
9. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:652-726
10. Galea J, Manche A, Goiti JJ, et al. Omission of aspirin in patients following coronary artery bypass graft surgery. J Clin Pharm Ther 1994;19:381-6
11. Bradshaw PJ, Jamrozik K, Gilfillan I, Thompson PL. Preventing recurrent events long term after coronary artery bypass graft: suboptimal use of medications in a population study. Am Heart J 2004;147:1047-53
12. The Post Coronary Artery Bypass Graft Trial Investigators. The Effect of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation on Obstructive Changes in Saphenous-Vein Coronary-Artery Bypass Grafts. New England Journal of Medicine 1997;336:153-163
13. Knatterud GL, Rosenberg Y, Campeau L, et al. Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial. Circulation 2000;102:157-165
14. Shah SJ, Waters DD, Barter P, et al. Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. Journal of the American College of Cardiology 2008;51:1938-43
15. Hamer AW, Takayama M, Abraham KA, et al. End-systolic volume and long-term survival after coronary artery bypass graft surgery in patients with impaired left ventricular function. Circulation 1994;90:2899-904
16. Allen JK, Blumenthal RS, Margolis S, Young DR. Status of secondary prevention in patients undergoing coronary revascularization. Am J Cardiol 2001;87:1203-6: A7
17. Bassand J-P, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. European Heart Journal 2007;28:1598-660
18. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. European Heart Journal 2008;29:2909-45
19. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. J Am Coll Cardiol 2008;51:210-47
20. Non ST-Elevation Myocardial Infarction Guidelines Group and the New Zealand Branch of The Cardiac Society of Australia and New Zealand. Non ST-elevation myocardial infarction: New Zealand management guidelines. N Z Med J 2005;118:U1680. http://www.nzma.org.nz/journal/118-1223/1680/
21. ST-Elevation Myocardial Infarction Guidelines Group and the New Zealand Branch of the Cardiac Society of Australia and New Zealand. ST-elevation myocardial infarction: New Zealand management guidelines. N Z Med J 2005;118:U1679. http://www.nzma.org.nz/journal/118-1223/1679 19/09/201119/09/2011
22. Fox DJ, Kibiro M, Eichhofer J, Curzen NP. Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention? Postgraduate Medical Journal 2005;81:401-3
23. Yam FK, Akers WS, Ferraris VA, et al. Interventions to improve guideline compliance following coronary artery bypass grafting. Surgery 2006;140:541-52
24. Turley AJ, Roberts AP, Morley R, et al. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up. Interact CardioVasc Thorac Surg 2008;7:231-4
25. Ellis C, O'Meeghan T, Hamer A, et al. Evidence based strategies for secondary prevention of ischaemic heart disease: time to improve clinical practice. NZ Med J 1998;111:170-2
26. Bramlage P, Messer C, Bitterlich N, et al. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart 2010;96:604-9
27. Goyal A, Alexander JH, Hafley GE, et al. Outcomes Associated With the Use of Secondary Prevention Medications After Coronary Artery Bypass Graft Surgery. Ann Thorac Surg 2007;83:993-1001
28. Okrainec K, Pilote L, Platt R, Eisenberg MJ. Use of cardiovascular medical therapy among patients undergoing coronary artery bypass graft surgery: results from the ROSETTA-CABG registry. Canadian Journal of Cardiology 2006;22:841-7
29. Ellis C, Zambanini A, French J, et al. Inadequate control of lipid levels in patients with a previous myocardial infarction. NZ Med J 1998;111:464-7
30. El-Jack S, Kerr A. Secondary prevention in coronary artery disease patients in South Auckland: moving targets and the current treatment gap. NZ Med J 2003;116:U664. http://www.nzma.org.nz/journal/116-1185/664/